Gilead Sciences, Inc. (GILD) は上場企業です ヘルスケア セクターの 製薬 業界で事業展開. 本社所在地は Foster City, CA, アメリカ. 現CEOは Daniel O'Day.
GILD を有する IPO日 1992-01-22, 17,600 名の正社員, に上場 NASDAQ Global Select, 時価総額 $174.33B.
Gilead Sciences, Inc. is a biopharmaceutical company headquartered in Foster City, California, that discovers, develops, and commercializes innovative medicines addressing unmet medical needs across the United States, Europe, and international markets. The company's portfolio spans multiple therapeutic areas, including HIV/AIDS treatment with leading antiretroviral products such as Biktarvy and Truvada, hepatitis C and liver disease management through Epclusa and Harvoni, oncology and cell therapy with products like Yescarta and Trodelvy, and other critical care areas including pulmonary arterial hypertension and serious fungal infections. Gilead also gained prominence for Veklury, its antiviral treatment for COVID-19. The company maintains strategic collaboration agreements with numerous leading biopharmaceutical and research organizations to advance its pipeline and expand its therapeutic capabilities.
